"Adrenocortical Carcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
| Descriptor ID |
D018268
|
| MeSH Number(s) |
C04.557.470.200.025.152 C04.588.322.078.265.750 C19.053.098.265.750 C19.053.347.500.750 C19.344.078.265.750
|
| Concept/Terms |
Adrenocortical Carcinoma- Adrenocortical Carcinoma
- Adrenocortical Carcinomas
- Carcinomas, Adrenocortical
- Carcinoma, Adrenocortical
- Carcinoma, Adrenal Cortical
- Adrenal Cortical Carcinoma
- Adrenal Cortical Carcinomas
- Carcinomas, Adrenal Cortical
|
Below are MeSH descriptors whose meaning is more general than "Adrenocortical Carcinoma".
Below are MeSH descriptors whose meaning is more specific than "Adrenocortical Carcinoma".
This graph shows the total number of publications written about "Adrenocortical Carcinoma" by people in this website by year, and whether "Adrenocortical Carcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenocortical Carcinoma" by people in Profiles.
-
Clinical outcomes of image-guided therapies in patients with adrenocortical carcinoma: a tertiary referral center retrospective study. Oncologist. 2024 Oct 03; 29(10):850-858.
-
Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis. Oncologist. 2024 Jul 05; 29(7):575-580.
-
Exogenous steroid replacement in a pediatric patient with adrenocortical carcinoma receiving mitotane. Pediatr Blood Cancer. 2024 Aug; 71(8):e31072.
-
Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol. 2024 May; 25(5):649-657.
-
Beyond the three P's: adrenal involvement in MEN1. Endocr Relat Cancer. 2024 Feb 01; 31(2).
-
The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study. Surgery. 2024 01; 175(1):80-89.
-
Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry. Endocr Pract. 2024 Jan; 30(1):25-30.
-
Adrenal Neoplasms: Lessons from Adrenal Multidisciplinary Tumor Boards. Radiographics. 2023 07; 43(7):e220191.
-
Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery. Ann Surg Oncol. 2023 02; 30(2):680-682.
-
Response to Letter to the Editor From de Ponthaud et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival." J Clin Endocrinol Metab. 2022 07 14; 107(8):e3540.